Evolent Health (EVH) EV to EBITDA (2015 - 2026)

Evolent Health has reported EV to EBITDA for 12 years, with the latest figure at 144.53 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 165.99% year-over-year to 144.53 in Q2 2026; TTM through Jun 2026 was 1.17, a 99.07% increase from a year earlier, with the FY2025 full-year figure at 0.69, up 99.38% from the prior year.
• EV to EBITDA was 144.53 for Q2 2026 at Evolent Health, down from 20.4 in the prior quarter.
• The five-year high for EV to EBITDA was 800.36 in Q2 2022, with the low at 1536.18 in Q1 2023.
• Average EV to EBITDA over 5 years is 57.1, with a median of 10.53 recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: EV to EBITDA jumped 414.85% in 2022, then tumbled 373.65% in 2023.
• Over 5 years, EV to EBITDA stood at 413.44 in 2022, then slumped by 163.14% to 261.03 in 2023, then jumped by 61.23% to 101.21 in 2024, then soared by 99.35% to 0.66 in 2025, then slumped by 21750.62% to 144.53 in 2026.
• The last three EV to EBITDA figures came in at 144.53 (Q2 2026), 20.4 (Q1 2026), and 0.66 (Q4 2025), per Business Quant data.